SLDB Solid Biosciences Inc.

4.66
+0.33  (+8%)
Previous Close 4.33
Open 4.42
Price To Book 1.98
Market Cap 214,302,081
Shares 45,987,571
Volume 751,062
Short Ratio
Av. Daily Volume 864,817
Stock charts supplied by TradingView

NewsSee all news

  1. Solid Biosciences Provides SGT-001 Program Update

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the

  2. Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at

  3. Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders¹ that summarizes the evidence

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial placed on clinical hold - November 12, 2019.
SGT-001
Duchenne Muscular Dystrophy

Latest News

  1. Solid Biosciences Provides SGT-001 Program Update

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the

  2. Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at

  3. Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders¹ that summarizes the evidence